A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Povorcitinib (Primary)
- Indications Chronic urticaria
- Focus Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
Most Recent Events
- 10 Feb 2025 According to Incyte media release, data from the study are anticipated in the first half of 2025.
- 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2023 Status changed from not yet recruiting to recruiting, as per a Incyte Corporation media release